CannLabs, Inc. (CANL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Denver, CO, United States. El CEO actual es Mark C. Mirken.
CANL tiene fecha de IPO 2014-06-13, 37 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $93.32K.
CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. is based in Denver, Colorado.
